SOMATROPIN DOSE ANALYSIS FOR TREATMENT OF HYPOPITUITARISM IN PUBLIC BRAZILIAN HEALTH SYSTEM (SUS)

Author(s)

Ferreira CN, Rufino CS, Manfrin DF
Pfizer, Inc., São Paulo, Brazil

OBJECTIVES: This analysis aims to determine, in International Units (IU), the somatropin volume waste of presentations with 4 IU and 12 IU compared to 16 IU and 36 IU, when used for treatment of Turner Syndrome and for children treatment with disorders of growth due to deficiencies of growth hormone. METHODS: The amount waste per month was analyzed, in IU, from the dosage indicated in the Project of Clinical Protocol Guideline (PCDT) for Hypopituitarism of the Brazilian Health Ministry and a comparative analysis was done between presentations of 4 IU/ 12 IU (approved by Ministry) and of 16 IU/ 36 IU. RESULTS: The average loss per treatment/month (Turner Syndrome and children with growth disorders) are 18,36 IU, 12,08 IU, 0,38 IU and 2,01 IU presentations with 4IU,12IU, 16IU and 36IU respectively. CONCLUSIONS: Therefore, if the SUS adopt presentations of 16IU or 36IU, that could be reduce the losses in an average of 97,5% and 87% respectively in month/patient, minimize the treatment cost, optimize doses number and achieve more patients. Moreover, it is more advantageous because they take up less space for storage and for transportation.

Conference/Value in Health Info

2014-05, ISPOR 2014, Palais des Congres de Montreal

Value in Health, Vol. 17, No. 3 (May 2014)

Code

PDB34

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis, Cost/Cost of Illness/Resource Use Studies

Disease

Diabetes/Endocrine/Metabolic Disorders, Rare and Orphan Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×